DUBLIN – Shares in Innate Pharma SA fell 14 percent Thursday on news that a data safety and monitoring board (DSMB) called a halt to one treatment arm of a phase II trial in acute myeloid leukemia (AML) testing lirilumab (IPH2102, BMS-986015), an immunotherapeutic antibody that targets inhibitory killer-cell immunoglobulin-like receptors (KIRs) expressed by natural killer (NK) cells.